University College Cork

Teagasc, the Agriculture and Food Development Authority

Artugen Therapeutics Ltd.

Agriculture and Food Development Authority (teagasc)

Csk Food Enrichment B.v.

Agriculture and Food Development Authority

Tate & Lyle Solutions USA LLC

Paul Ross

Colin Hill

Catherine Stanton

Mary Rea

Ronald Farquhar

Christopher K Murphy

Brian Healy

Fergus Shanahan

John Francis Cryan

Michelle O'Donnell

Laurent Chesnel

Stephen Hallahan

Noel Caplice

Willem Cornelis Meijer

Lourdes Mariela Serrano Davalos

Desmond Field

Paul Cotter

Gerald F Fitzgerald

Ger Fitzgerald

Susan Mills

Carmel Griffin

William Meaney

Tony Ryan

Ieva Laurie

Kavita Karnik

Kirstie Canene-Adams

Florence Herisson

Ted Dinan

Colin Department Of Microbiology Hill

Ger Department Of Microbiology Fitzgerald

A composition for use in a method of regulating or treating a metabolic disease or a symptom thereof, the composition comprising an isolated bacteria(DPC6108) deposited with the National Collection of Industrial and Marine Bacteria Limited (NCIMB) on 28 Nov. 2011 and accorded the accession number NCIMB 41903.

GABA-producing culturable bacteria and use for improving health

Disclosed herein are compositions and methods for preventing, ameliorating, or treatinginfections and/or reducing the severity of one or more risk factors, signs, or symptoms associated withinfections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains ofbacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk forinfections.

Methods and compositions for the treatment of C. difficile

Disclosed herein are compositions and methods for preventing, ameliorating, or treatinginfections and/or reducing the severity of one or more risk factors, signs, or symptoms associated withbacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk forinfections.

An isolated(DPC6426) strain deposited with the National Collection of Industrial and Marine Bacteria Limited (NCIMB) on 27 Jul. 2012 under NCIMB Deposit Accession No. 42015.

Exopolysaccharide-producing bacteria, and uses thereof for protecting heart health

The disclosure relates to the live cultures of probiotic bacteria to treat infectious diseases in humans and animals. Food-grade or non-pathogenic cultures are used to treat localised infections.

Use of probiotic bacteria in the treatment of infection

The present invention discloses a method for producing a fermented dairy product, preferably cheese, comprising inoculating milk with lactic acid bacteria capable of producing a Class IIa type bacteriocin; and lactic acid bacteria capable of producing a Class I type bacteriocin.

Anti-listerial mixed culture and method for producing cheese

A Nisin derivative or variant, comprising an amino acid substitution at amino acid position 29 in the amino acid sequence. The Nisin derivative exhibits enhanced antimicrobial activity when compared to wild type Nisin. The Nisin derivative has an application as a natural food additive and as a therapeutic agent.

Mutant Nisin ser 29 derivatives and the use thereof

The present invention relates to a new bacteriocin, to microbial strains which can produce it and to uses of the bacteriocin and the strains. The bacteriocin is effective againstandamongst other organisms.

[object Object]

The invention provides a probiotic composition to alleviateinfection in farm animals. The composition may comprise at least one ofsub-species, and. The composition maybe formulated as an animal feedstuff, or as a pharmaceutical composition.

Probiotic composition suitable for animals

Growing community of inventors

Cork, Ireland

Paul Ross